Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Diamyd versus placebo in recent-onset type 1 diabetes
NL-OMON58772Phase 3Completed
- Sponsor
- Diamyd Medical
- Start
- Sep 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Diamyd in diabetes mellitus type 1 (T1D), sponsored by Diamyd Medical. Primary endpoints: Change from baseline to Month 15 in C-peptide AUC mean 0-120 min during a 2-hour MMTT and Change from baseline to Month 15 in HbA1c. Started Sep 2022; status: completed.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON58772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58772.